The most successful VEGF inhibitor is the humanized VEGF-neutralizing antibody bevacizumab, which exerts its anti-angiogenic activity by acting against the angiogenic endothelial cells surrounding the tumor, rather than the tumor per se, thus blocking the supply of oxygen and nutrients to the tumors (46–48). The gene discussed is VEGFA; the disease is neoplasm.